Abstract
Duchenne muscular dystrophy (DMD) is a severe X-linked recessive neuromuscular disorder-affecting males, exclusively. DMD has a worldwide reported incidence of 1 per 3500–9000 male children. Although very rare, some cases have been observed in carrier females. DMD is caused by deletions, duplications and point mutations in the DMD gene. However, most of the molecular mutations are deletions in DMD gene that encodes dystrophin, the altered protein in Duchenne and Becker muscular dystrophy. The affected patients have progressive muscle weakness and will be wheelchair bound before or during their teens and eventually develop respiratory and cardiac dysfunction. In addition to the standard supportive therapy, recently there are many emerging genetic therapies for DMD targeting repair of the primary genetic defect. The purpose of this talk is to present the phenotypic and genetic spectrum of DMD patients in Qatar and highlight some of the genetic counseling aspects pertinent to the Qatari population.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
